Portal de Periódicos da CAPES

Surfactant treatment for acute respiratory distress syndrome

1999; BMJ; Volume: 80; Issue: 3 Linguagem: Inglês

10.1136/adc.80.3.248

1468-2044

Jesús López‐Herce, Nieves de Lucas, Atilio Moreno, Amaya Bustinza, Ramón Moral,

Neuroscience of respiration and sleep

To determine prospectively the efficacy of surfactant in acute respiratory distress syndrome.Twenty patients, 1 month to 16 years of age, diagnosed with an acute pulmonary disease with severe hypoxaemia (PaO2/FiO2 < 100) (13 with systemic or pulmonary disease and seven with cardiac disease) were treated with one to six doses of 50-200 mg/kg of porcine surfactant administered directly into the trachea. The surfactant was considered to be effective when the PaO2/FiO2 improved by > 20%.After initial surfactant administration the PaO2/FiO2 increased significantly in patients with systemic or pulmonary disease from 68 to 111, and the oxygenation index (OI) diminished significantly from 36.9 to 27.1. The PaO2/FiO2 and OI did not improve in children with cardiac disease. The improvement of the patients who survived was greater than that of those who died.Surfactant moderately improves oxygenation in some children with severe acute respiratory distress syndrome secondary to pulmonary or systemic disease.